ArticleMediators of inflammation2013
Usefulness of adalimumab in the treatment of refractory uveitis associated with juvenile idiopathic arthritis.
Article in Mediators of inflammation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Epidemiological and advanced therapeutic approaches to treatment of uveitis in pediatric rheumatic diseases: a systematic review and meta-analysis.Orphanet journal of rare diseases · 2020Pooled it
- Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans for Juvenile Idiopathic Arthritis-Associated and Idiopathic Chronic Anterior Uveitis.Arthritis care & research · 2019Guideline
- Efficacy and safety of adalimumab in the treatment of non-infectious uveitis: a meta-analysis and systematic review.Drug design, development and therapy · 2018Pooled it
- Systemic Immunomodulatory Therapy, Anterior Chamber Inflammation, and the Use of Topical Corticosteroids in Juvenile Idiopathic Arthritis-Associated Uveitis: A Long-Term Real-Life Observational Study.Journal of clinical medicine · 2026Article
- Dose Exploration Based on Quantitative Pharmacokinetic Analysis of Monoclonal Antibodies for Pediatric Immune-Mediated Diseases: Current Evidence and Future Directions.Drug design, development and therapy · 2026Review
- Diagnosis and treatment of uveitis associated with juvenile idiopathic arthritis.Medicine and pharmacy reports · 2021Article
- Endothelin-1 Serum Concentration in Pediatric Chronic Idiopathic Uveitis.Clinical ophthalmology (Auckland, N.Z.) · 2021Article
- Uveitis in juvenile idiopathic arthritis.World journal of pediatrics : WJP · 2020Review
- Biological therapy in refractory cases of uveitis and scleritis: An analysis of 18 cases from a tertiary eye care center from South India.Indian journal of ophthalmology · 2020Observational
- Experience of using adalimumab in treating sight-threatening paediatric or adolescent Behcet's disease-related uveitis.Journal of ophthalmic inflammation and infection · 2019Article
- Timing of infliximab and adalimumab initiation despite methotrexate in children with chronic non-infectious anterior uveitis.Eye (London, England) · 2019Article
- Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative.Annals of the rheumatic diseases · 2018Article
- Outcome of Juvenile Idiopathic Arthritis Associated Uveitis in Two Disease Subtypes.Archives of rheumatology · 2017Article
- An Update on Treatment of Pediatric Chronic Non-Infectious Uveitis.Current treatment options in rheumatology · 2017Article
- Discontinuation of long-term adalimumab treatment in patients with juvenile idiopathic arthritis-associated uveitis.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2017Article
- Factors associated with choice of biologic among children with Juvenile Idiopathic Arthritis: results from two UK paediatric biologic registers.Rheumatology (Oxford, England) · 2016Observational
- Biologics in Pediatric Rheumatology: Quo Vadis?Current rheumatology reports · 2016Review
- [Uveitis associated with juvenile idiopathic arthritis : Optimization of immunomodulatory therapy].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2016Review
- The Use of Biologic Therapies in Uveitis.Clinical reviews in allergy & immunology · 2015Review
- Clinical management algorithm of uveitis associated with juvenile idiopathic arthritis: interdisciplinary panel consensus.Rheumatology international · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 12 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess the efficacy and safety of adalimumab in patients with juvenile idiopathic arthritis (JIA) and associated refractory uveitis.
designMulticenter, prospective case series.
methodsThirty-nine patients (mean [SD] age of 11.5 [7.9] years) with JIA-associated uveitis who were either not responsive to standard immunosuppressive therapy or intolerant to it were enrolled. Patients aged 13-17 years were treated with 40 mg of adalimumab every other week for 6 months and those aged 4-12 years received 24 mg/m(2) body surface.
resultsInflammation of the anterior chamber (2.02 [1.16] versus 0.42 [0.62]) and of the posterior segment (2.38 [2.97] versus 0.35 [0.71] decreased significantly between baseline and the final visit (P < 0.001). The mean (SD) macular thickness at baseline was 304.54 (125.03) μ and at the end of follow-up was 230.87 (31.12) μ (P < 0.014). Baseline immunosuppression load was 8.10 (3.99) as compared with 5.08 (3.76) at the final visit (P < 0.001). The mean dose of corticosteroids also decreased from 0.25 (0.43) to 0 (0.02) mg (P < 0.001). No significant side effects requiring discontinuation of therapy were observed.
conclusionAdalimumab seems to be an effective and safe treatment for JIA-associated refractory uveitis and may reduce steroid requirement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.